UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 84

Sortiert nach

Zeitmanagement

Jörg Knoblauch, Holger Wöltje, Marcus B. Hausner, Martin Kimmich, Siegfried Lachmann

2019

Volltextzugriff (PDF)

Carcinoma, tuberculosis, atypical pneumonia - or may be pulmonary tularemia? Two case reports

Pneumologie (Stuttgart, Germany), 2024-03, Vol.78 (3), p.199

2024

Volltextzugriff (PDF)

Phase II Trial of a Trimodality Regimen for Stage III Non–Small-Cell Lung Cancer Using Chemotherapy As Induction Treatment With Concurrent Hyperfractionated Chemoradiation With Carboplatin and Paclitaxel Followed by Subsequent Resection: A Single-Center Study

Journal of clinical oncology, 2010-02, Vol.28 (6), p.942-948

2010

Volltextzugriff (PDF)

Zeitmanagement

5, 2023

Volltextzugriff (PDF)

Primary Pulmonary Synovial Sarcoma: A Rare Primary Pulmonary Tumor

Lung, 2014-02, Vol.192 (1), p.211-214

2014

Volltextzugriff (PDF)

A randomized, multicenter phase II study comparing efficacy, safety and tolerability of two dosing regimens of cisplatin and pemetrexed in patients with advanced or metastatic non-small-cell lung cancer

Therapeutic advances in medical oncology, 2021, Vol.13, p.1758835921996506

2021

Volltextzugriff (PDF)

Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial

The lancet oncology, 2019-12, Vol.20 (12), p.1655-1669

2019

Volltextzugriff (PDF)

Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer

The New England journal of medicine, 2017-02, Vol.376 (7), p.629-640

2017

Volltextzugriff (PDF)

A Randomized-Controlled Phase 2 Study of the MET Antibody Emibetuzumab in Combination with Erlotinib as First-Line Treatment for EGFR Mutation–Positive NSCLC Patients

Journal of thoracic oncology, 2020-01, Vol.15 (1), p.80-90

2020

Volltextzugriff (PDF)

Pembrolizumab vs placebo for early-stage non‒small-cell lung cancer after resection and adjuvant therapy: Subgroup analysis of patients who received adjuvant chemotherapy in the phase 3 PEARLS/KEYNOTE-091 study

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.8520-8520

2023

Volltextzugriff (PDF)

Prognostic factors in nonsmall cell lung cancer: insights from the German CRISP registry

The European respiratory journal, 2023-02, Vol.61 (2), p.2201336

2023

Volltextzugriff (PDF)

Abstract 1224: Combination of rapamycin and crizotinib induces partial remission of pleural mesothelioma in a patient-derived xenograft model

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.1224-1224

2017

Volltextzugriff (PDF)

Efficacy and safety analysis of the German expanded access program of osimertinib in patients with advanced, T790M-positive non-small cell lung cancer

Journal of cancer research and clinical oncology, 2018-12, Vol.144 (12), p.2457-2463

2018

Volltextzugriff (PDF)

Experience With Afatinib in Patients With Non‐Small Cell Lung Cancer Progressing After Clinical Benefit From Gefitinib and Erlotinib

The oncologist (Dayton, Ohio), 2014-10, Vol.19 (10), p.1100-1109

2014

Volltextzugriff (PDF)

Clinical Experience of Immunotherapy Treatment: Efficacy and Toxicity Analysis of the Compassionate Use Program of Nivolumab in Patients with Advanced Squamous Cell Non-Small Cell Lung Cancer

Oncology research and treatment, 2019-01, Vol.42 (5), p.243-255

2019

Volltextzugriff (PDF)

Checkpoint Inhibitor Monotherapy in Potentially Trial-Eligible or Trial-Ineligible Patients With Metastatic NSCLC in the German Prospective CRISP Registry Real-World Cohort (AIO-TRK-0315)

JTO clinical and research reports, 2024-04, Vol.5 (4), p.100626-100626, Article 100626

2024

Volltextzugriff (PDF)

Efficacy and Safety of Ramucirumab With Docetaxel Versus Placebo With Docetaxel as Second-Line Treatment of Advanced Non–Small-Cell Lung Cancer: A Subgroup Analysis According to Patient Age in the REVEL Trial

Clinical lung cancer, 2018-05, Vol.19 (3), p.270-279.e3

2018

Volltextzugriff (PDF)

Open-label, randomized study of individualized, pharmacokinetically (PK)-guided dosing of paclitaxel combined with carboplatin in advanced non-small cell lung cancer (NSCLC) patient

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.8051-8051

2015

Volltextzugriff (PDF)

Late lung metastasis of primary endometrial cancer: Two rare cases of patients with late lung metastasis of primary endometrial cancer 14 and 17 years after initial treatment

Memo - Magazine of European medical oncology, 2012-12, Vol.5 (4), p.262-265

2012

Volltextzugriff (PDF)

Intro

Zeitmanagement, 2023

2023

Volltextzugriff (PDF)

Impressum

Zeitmanagement, 2023

2023

Volltextzugriff (PDF)

Weitere Literatur

Zeitmanagement, 2023

2023

Volltextzugriff (PDF)

1 – 25 von 84

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(46)
Mit Volltextzugriff
(80)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Englisch
(50)
Deutsch
(34)
Japanisch
(3)

Erscheinungsjahr

n.n

Thema

Science & Technology
(38)
Life Sciences & Biomedicine
(33)
Humans
(23)
Female
(17)
Male
(17)
Oncology
(16)
Aged
(15)
Middle Aged
(15)
Adult
(14)
Clinical Neurology
(7)
Hematology
(7)
Lung Neoplasms - Drug Therapy
(7)
Lung Neoplasms - Pathology
(7)
Mutation
(7)
Neurosciences & Neurology
(7)
Treatment Outcome
(7)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(6)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(6)
Carcinoma, Non-Small-Cell Lung - Pathology
(6)
Lung Cancer
(6)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Zeitmanagement

Carcinoma, tuberculosis, atypical pneumonia - or may be pulmonary tularemia? Two case reports

Phase II Trial of a Trimodality Regimen for Stage III Non–Small-Cell Lung Cancer Using Chemotherapy As Induction Treatment With Concurrent Hyperfractionated Chemoradiation With Carboplatin and Paclitaxel Followed by Subsequent Resection: A Single-Center Study

Zeitmanagement

Primary Pulmonary Synovial Sarcoma: A Rare Primary Pulmonary Tumor

A randomized, multicenter phase II study comparing efficacy, safety and tolerability of two dosing regimens of cisplatin and pemetrexed in patients with advanced or metastatic non-small-cell lung cancer

Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial

Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer

Phase III Study of Surgery Versus Definitive Concurrent Chemoradiotherapy Boost in Patients With Resectable Stage IIIA(N2) and Selected IIIB Non-Small-Cell Lung Cancer After Induction Chemotherapy and Concurrent Chemoradiotherapy (ESPATUE)

A Randomized-Controlled Phase 2 Study of the MET Antibody Emibetuzumab in Combination with Erlotinib as First-Line Treatment for EGFR Mutation–Positive NSCLC Patients

Pembrolizumab vs placebo for early-stage non‒small-cell lung cancer after resection and adjuvant therapy: Subgroup analysis of patients who received adjuvant chemotherapy in the phase 3 PEARLS/KEYNOTE-091 study

Prognostic factors in nonsmall cell lung cancer: insights from the German CRISP registry

Abstract 1224: Combination of rapamycin and crizotinib induces partial remission of pleural mesothelioma in a patient-derived xenograft model

Efficacy and safety analysis of the German expanded access program of osimertinib in patients with advanced, T790M-positive non-small cell lung cancer

Experience With Afatinib in Patients With Non‐Small Cell Lung Cancer Progressing After Clinical Benefit From Gefitinib and Erlotinib

Clinical Experience of Immunotherapy Treatment: Efficacy and Toxicity Analysis of the Compassionate Use Program of Nivolumab in Patients with Advanced Squamous Cell Non-Small Cell Lung Cancer

A randomized, controlled, open label phase II study of erlotinib (E) with or without the MET antibody emibetuzumab (Emi) as first-line treatment for EGFR mt non-small cell lung cancer (NSCLC) patients who have disease control after an 8-week lead-in treatment with erlotinib

Checkpoint Inhibitor Monotherapy in Potentially Trial-Eligible or Trial-Ineligible Patients With Metastatic NSCLC in the German Prospective CRISP Registry Real-World Cohort (AIO-TRK-0315)

Efficacy and Safety of Ramucirumab With Docetaxel Versus Placebo With Docetaxel as Second-Line Treatment of Advanced Non–Small-Cell Lung Cancer: A Subgroup Analysis According to Patient Age in the REVEL Trial

Open-label, randomized study of individualized, pharmacokinetically (PK)-guided dosing of paclitaxel combined with carboplatin in advanced non-small cell lung cancer (NSCLC) patient

Phase III study of surgery (S) versus definitive concurrent chemoradiotherapy boost (def ccCRTx-BOx) in patients (pts) with operable (OP+) stage IIIA(N2)/selected IIIb (sel IIIB) non-small cell lung cancer (NSCLC) following induction (IND) chemotherapy (CTx) and concurrent CRTx (ESPATUE)

Late lung metastasis of primary endometrial cancer: Two rare cases of patients with late lung metastasis of primary endometrial cancer 14 and 17 years after initial treatment

Intro

Impressum

Weitere Literatur

Suchergebnisse filtern